Pharmaceutical sponsor
Beijing Mabworks Biotech Co., Ltd. Clinical Trials
Studies where Beijing Mabworks Biotech Co., Ltd. is the lead sponsor: its pipeline by phase, what is enrolling now and where. Studies it supports as a collaborator are in the search.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 6Multiple Myeloma
A Study of MBS314 for Injection in Participants With Relapsed/Refractory Multiple Myeloma.
This is a Phase I/II, multicenter, open-label, dose-escalation and dose-expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of MBS314, a novel asymmetric…
- Trial name
- NCT07911748
- Testing
- MBS314 for Injection
- Volunteers
- 78 people
- Sponsor
- Beijing Mabworks Biotech Co., Ltd.
Systemic Lupus Erythematosus
A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus
This study will evaluate the efficacy and safety of MIL62 compared with placebo in participants with systemic lupus erythematosus.
- Trial name
- NCT07405970
- Testing
- MIL62
- Where
- China
- Volunteers
- 316 people
- Sponsor
- Beijing Mabworks Biotech Co., Ltd.
Immunoglobulin A Nephropathy
A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.
This is a Phase I/II study designed to evaluate the safety, tolerability, PK and PD of subcutaneous MIL116, an anti-APRIL monoclonal antibody, in healthy participants and patients with IgA Nephropathy.
- Trial name
- NCT07375758
- Testing
- MIL116
- Where
- China
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Beijing Mabworks Biotech Co., Ltd.
Non-Hodgkin's Lymphoma
A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL
This is a Phase I/Ⅱ, multicenter, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics(PD) and efficacy of a novel T-Cell bispecific (TCB), MBS303, administered…
- Trial name
- NCT05806099
- Testing
- MBS303
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Beijing Mabworks Biotech Co., Ltd.
Relapsed or Refractory Multiple Myeloma
A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.
This is a Phase I/Ⅱ, multicenter, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics(PD) and efficacy of a novel asymmetric trivalent tri-specific humanized…
- Trial name
- NCT06232096
- Testing
- MBS314 Injection
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Beijing Mabworks Biotech Co., Ltd.
Advanced or Metastatic Solid Tumor
Treatment of Advanced and Metastatic Solid Tumors With MIL97
This is a Phase 1, global, multi-center, open-label, multiple-dose, first-in-human study of MIL97 to evaluate the safety, tolerability, pharmacokinetics, biomarkers and efficacy in subjects with advanced or metastatic solid…
- Trial name
- NCT04965077
- Testing
- Recombinant Humanized Monoclonal Antibody MIL97 for Injection
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Beijing Mabworks Biotech Co., Ltd.